AstraZeneca PLC announced on Tuesday that its revenue in the first quarter of the fiscal year 2025 saw an annual actual rise of 7%, 10% at constant exchange rate (CER), to hit $13.6 billion.The pharmaceutical company's product sales went up by 6%, 9% at CER year-on-year to reach $12.9 billion,...
Stocks of major European pharmaceutical companies, including French Sanofi, British GSK and AstraZeneca, as well as Swiss Roche and Novartis, saw a decline on Wednesday following US President Donald Trump's announcement of a "major tariff" on pharmaceuticals. Trump revealed that Washington...
AstraZeneca announced on Friday the investment of $2.5 billion in Beijing to establish its second strategic research and development (R&D) center in China and sixth worldwide. AstraZeneca projects its Beijing staff count will reach 1,700 personnel."This $2.5 billion investment reflects our belief in the...
AstraZeneca announced on Monday that it entered into a definitive agreement to acquire biotechnology company EsoBiotec SA for up to $1 billion in cash."We look forward to working with AstraZeneca, a global leader in drug development, to advance our shared goal of bringing transformative...
AstraZeneca Plc. announced on Thursday that its revenue in the fourth quarter of its fiscal 2024 rose by 24% on an annual basis to $14.9 billion, exceeding analysts' expectations. For the full 2024, total revenue jumped by 21% to $54.1 billion.The company's diluted earnings per share (EPS)...
AstraZeneca plc has decided not to proceed with plans to build a vaccine plant near Liverpool, the company told the Financial Times on Friday. "Following protracted discussions with the government, we are no longer pursuing our planned investment at Speke," AstraZeneca said, citing several...
AstraZeneca Plc.'s treatment for patients with unresectable non-small cell lung cancer Tagrisso gained key recommendation for approval in the European Union, the company announced on Monday.The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
AstraZeneca plc shared on Tuesday that in the third quarter of fiscal 2024 its total revenue grew 21% year over year to reach $13.5 billion. On an annual basis, core earnings per share saw a rise of 27%, standing at $2.08, while operating profit added 18% to $2.1 billion.In the nine months ending...
AstraZeneca PLC announced on Thursday its revenue in the second quarter of the fiscal year 2024 saw an annual increase of 13% to hit $12.94 billion. In the first half of the year, the figure advanced by 15% to $25.62 billion.The company's product sales grew by 14% compared to 2023's second...
AstraZeneca stated on Tuesday that it intends to deliver a total revenue of $80 billion by 2023, up from $45.8 billion in 2020.
According to the company, the milestone will "be achieved through significant growth in its existing oncology, biopharmaceuticals, and rare disease portfolio, and by...
This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.
